Context Therapeutics Inc. CNTX
0.35
(0.02)
(5.41%)
as of 25 Sep
- Market cap
- $34.1M
- P/E
- 0.0×
Follow CNTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
8.52 | 35.62 | 3.83 | 11.80 | 16.90 | 0.03 | 0.01 | — |
Net Debt/EBITDA |
1.66 | 3.16 | 0.58 | 2.31 | 4.72 | (2.18) | (4.02) | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.15% | 0.00% | 1,262.21% | 7,986.44% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.35) | (0.92) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.73 | 0.54 | 0.88 | 0.91 | 0.84 | (0.97) | 0.44 | — |
Capex/Depreciation |
(2.08) | (0.67) | 0.00 | (3.96) | — | — | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (46.39%) | (49.89%) | (102.79%) | (35.74%) | (66.71%) | (5.24%) | 31.23% | — | |
| (43.36%) | (46.81%) | (88.71%) | (33.24%) | (40.40%) | 289.12% | (4,668.52%) | — | |
ROIC |
0.00% | (2,235.80%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(59.84%) | (28.08%) | (201.87%) | (42.79%) | (21.68%) | (11.58%) | 26.75% | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.28) | (0.25) | (1.32) | (0.85) | (3.10) | (2.97) | (0.26) | — |
Cash per Share |
0.69 | 1.62 | 0.91 | 2.22 | 17.51 | 0.84 | 0.02 | — |
Shareholders Equity per Share |
0.64 | 1.63 | 0.74 | 2.18 | 17.03 | (48.62) | (2.17) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.64 | 1.63 | 0.74 | 2.18 | 17.03 | (48.62) | (2.17) | — |
Free Cash Flow |
(26.42) | (14.56) | (21.05) | (13.59) | (8.80) | (1.03) | (2.84) | — |
Working Capital |
60.33 | 95.15 | 11.86 | 34.65 | 48.22 | (9.25) | (23.87) | — |
Capital Expenditures |
(0.03) | (0.01) | — | (0.04) | — | — | — | — |
Net Current Asset Value |
60.33 | 95.04 | 11.86 | 34.65 | 48.22 | (17.09) | (23.87) | — |
| Other line items | ||||||||
Quick Ratio |
8.23 | 34.36 | 3.45 | 11.07 | 16.36 | 0.03 | 0.01 | — |
Depreciation/Fixed assets |
0.55 | 0.91 | 0.77 | 0.34 | — | — | — | — |
Cash ROIC |
(20.89%) | (7.68%) | (80.02%) | (19.31%) | (8.99%) | 9.64% | 160.66% | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.28) | (0.25) | (1.32) | (0.85) | (3.10) | (2.97) | (0.26) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
1.99 | 1.92 | 1.66 | 1.38 | 2.27 | 2.39 | 2.39 | — |
Average Assets |
83.31 | 57.09 | 27.01 | 44.64 | 25.89 | 0.37 | 0.14 | — |
Average Common Equity |
77.87 | 53.57 | 23.31 | 41.52 | 15.68 | (20.44) | (20.44) | — |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | — | — | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates